Anika Therapeutics

Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. The Company is committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. 
Anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care and skin rejuvenation. The Company's proprietary technology is based on hyaluronic acid, a naturally occurring polymer found throughout the body vital for proper joint health and tissue function. Its products include MONOVISC®, ORTHOVISC®, and ORTHOVISC® mini used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; ELEVESS® cosmetic dermal filler with lidocaine; ANIKAVISC® viscoelastic for ophthalmic surgery; INCERT®-S anti-adhesion surgical gel; and next generation products for joint health, advanced wound care and other applications.
At Anika, they believe that an individual’s feelings about their age are driven by perceptions about the state of their body.
Company Growth (employees)
Bedford, US
Size (employees)
122 (est)
Anika Therapeutics was founded in 1992 and is headquartered in Bedford, US

Anika Therapeutics Office Locations

Anika Therapeutics has offices in Bedford and Ponte Fabbrica
Bedford, US (HQ)
32 Wiggins Ave
Ponte Fabbrica, IT
3 Via Ponte della Fabbrica
Show all (2)

Anika Therapeutics Financials and Metrics

Anika Therapeutics Financials

Anika Therapeutics's revenue was reported to be $103.4 m in FY, 2016

Revenue (Q3, 2017)

27.2 m

Net income (Q3, 2017)

6.9 m

EBIT (Q3, 2017)

10.3 m

Market capitalization (22-Dec-2017)

789.3 m

Cash (30-Sep-2017)

127 m
Anika Therapeutics's current market capitalization is $789.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


75.1 m105.6 m93 m103.4 m

Revenue growth, %


Cost of goods sold

22.8 m20.9 m21.1 m24 m

Gross profit

52.3 m84.7 m71.9 m79.4 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


17.8 m34 m26.3 m22.1 m15.5 m22.9 m23.7 m22.3 m26.6 m25.8 m23.4 m33.5 m27.2 m

R&D expense

4.4 m5.8 m

General and administrative expense

5 m4.8 m

Operating expense total

10 m10.1 m11.1 m11.8 m10 m10.5 m10.5 m11.6 m13.1 m12.1 m15.4 m15.7 m16.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


63.3 m100.2 m110.7 m104.3 m


11 m12.4 m14.9 m16 m

Current Assets

94.6 m139 m176.4 m170.4 m


52.4 m53.6 m40.1 m52.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


64.1 m82.2 m84.9 m71.8 m99.8 m103.9 m108.5 m92.8 m89.1 m98 m119.4 m117.9 m127 m


11.6 m13 m13.9 m13.6 m12.5 m11.7 m12.1 m15.8 m17.3 m18 m16.2 m17.6 m20.3 m

Current Assets

95 m113.5 m119.5 m128.7 m145.9 m155.7 m168.3 m147.9 m154.6 m161.1 m177.1 m192.9 m199 m


31.5 m33.8 m46.8 m49.2 m51.1 m51.6 m52.3 m54 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

20.6 m38.3 m30.8 m32.5 m

Depreciation and Amortization

4.8 m4.7 m3.8 m3.7 m

Accounts Receivable

2.4 m897.6 k(5 m)(6.2 m)


(2.8 m)(2 m)(2.9 m)(1.7 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

5 m15 m9.3 m6.2 m3.5 m7.8 m8.4 m6.9 m8.6 m9 m5.5 m


13.9 m13.6 m12.5 m11.7 m12.1 m15.8 m17.3 m18 m16.2 m

Accounts Payable

2.2 m1.2 m1.8 m1.7 m2.2 m3.3 m3.3 m1.9 m6.1 m
USDY, 2017


222.8 k

Financial Leverage

1.1 x
Show all financial metrics

Anika Therapeutics Operating Metrics

FY, 2016

Patents (US)


Patents (foreign)


Patents Licensed


Patents Pending

Show all operating metrics

Anika Therapeutics Market Value History

Anika Therapeutics's Web-traffic and Trends

Anika Therapeutics Online and Social Media Presence

Anika Therapeutics Company Life and Culture

You may also be interested in